Etelcalcetidum

Etelcalcetidum Uses, Dosage, Side Effects, Food Interaction and all others data.

Etelcalcetidum is a calcimimetic drug for the treatment of secondary hyperparathyroidism in patients undergoing hemodialysis. Etelcalcetidum was approved (trade name Parsabiv) for the treatment of secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on hemodialysis in February, 2017.

Following a single intravenous bolus administration of etelcalcetide, PTH levels decreased within 30 minutes post dose. In the single-dose study, the extent and duration of the reduction in PTH increased with increasing dose. Reduction in PTH levels correlated with plasma etelcalcetide concentrations in hemodialysis patients. The reduction in PTH resulted in reductions in calcium and attenuation of post-dialytic phosphate elevation. The effect of reducing PTH levels was maintained throughout the 6-month dosing period when etelcalcetide was administered by intravenous bolus three times a week.

Etelcalcetidum
Uses
Dosage
Side Effect
Precautions
Interactions
Uses during Pregnancy
Uses during Breastfeeding
Accute Overdose
Food Interaction
Half Life
Volume of Distribution
Clearance
Interaction With other Medicine
Contradiction
Storage

Trade Name	Etelcalcetidum
Availability	Prescription only
Generic	Etelcalcetide
Etelcalcetide Other Names	Etelcalcetida, Etelcalcetide, ételcalcétide, Etelcalcetidum, Velcalcetide
Related Drugs	Rayaldee, Parsabiv, calcifediol
Type
Formula	C₃₈H₇₃N₂₁O₁₀S₂
Weight	Average: 1048.26 Monoisotopic: 1047.529069983
Protein binding	Etelcalcetide is predominately bound to plasma albumin by reversible covalent binding. Non-covalent binding of etelcalcetide to plasma proteins is low with a fraction unbound ratio of 0.53. The ratio of blood-to-plasma [14C]-etelcalcetide concentrations is approximately 0.6.
Groups	Approved, Investigational
Therapeutic Class
Manufacturer
Available Country
Last Updated:	September 19, 2023 at 7:00 am

Uses

Etelcalcetidum is a calcium sensing receptor agonist used to treat secondary hyperparathyroidism in patients with chronic kidney disease who require hemodialysis.

Etelcalcetidum is a calcium-sensing receptor agonist indicated for: Secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on hemodialysis.

Etelcalcetidum is also used to associated treatment for these conditions: Secondary Hyperparathyroidism (SHPT)

How Etelcalcetidum works

Etelcalcetidum is a calcimimetic agent that allosterically modulates the calcium-sensing receptor (CaSR). Etelcalcetidum binds to the CaSR and enhances activation of the receptor by extracellular calcium. Activation of the CaSR on parathyroid chief cells decreases PTH secretion.

Food Interaction

No interactions found.

Etelcalcetidum Disease Interaction

Moderate: arrhythmia, GI bleeding, heart failure, seizures

Volume of Distribution

796 L

Elimination Route

The pharmacokinetics of etelcalcetide is linear and does not change over time following single (5 to 60 mg) and multiple intravenous doses (2.5 to 20 mg) in chronic kidney disease patients with secondary hyperparathyroidism requiring hemodialysis. Etelcalcetidum exhibited tri-exponential decay following intravenous administration. Based on population pharmacokinetic analysis, following three times a week intravenous dosing at the end of each 3- to 6-hour hemodialysis session in chronic kidney disease patients, etelcalcetide plasma levels reached steady state in 7-8 weeks after dosing with a predicted accumulation ratio of 3- to 4-fold